Synmosa Biopharma Corporation (TPEX:4114)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
New Drugs Segment			4.96B	4.24B	3.15B	2.92B	2.53B
New Drugs Segment Growth			17.05%	34.70%	7.61%	15.46%	13.90%
Pharmaceutical Ingredients Department			325.78M	234.87M	119.57M	152.56M	173.85M
Pharmaceutical Ingredients Department Growth			38.71%	96.43%	-21.63%	-12.25%	17.58%
Intersegment Income			-146.19M	-86.89M	-31.13M	-38.34M	-26.41M
Total			5.14B	4.39B	3.23B	3.04B	2.68B
Total Growth			17.19%	35.59%	6.47%	13.37%	13.40%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Taiwan			4.45B	3.88B	2.81B	2.62B	2.37B
Taiwan Growth			14.83%	37.79%	7.43%	10.46%	16.07%
China			450.98M	271.73M	293.58M	301.67M	174.93M
China Growth			65.97%	-7.44%	-2.68%	72.46%	8.27%
USA			28.78M	62.74M	8.66M	-	-
USA Growth			-54.12%	624.84%	-	-	-
Canada			15.50M	34.97M	30.29M	11.76M	-
Canada Growth			-55.68%	15.43%	157.61%	-	-
Thailand			54.56M	39.60M	23.16M	25.88M	25.03M
Thailand Growth			37.79%	70.99%	-10.52%	3.42%	-11.62%
Malaysia			36.45M	30.75M	19.41M	19.09M	24.92M
Malaysia Growth			18.54%	58.38%	1.67%	-23.39%	1.83%
Singapore			41.91M	-	-	-	-
Other			60.80M	70.10M	46.47M	60.99M	84.12M
Other Growth			-13.28%	50.85%	-23.80%	-27.50%	-20.73%
Total			5.14B	4.39B	3.23B	3.04B	2.68B
Total Growth			17.19%	35.59%	6.47%	13.37%	13.40%

Source: S&P Global Market Intelligence.